Bringing the fundamentals into focus…
Back to Can-Fite BioPharma Ltd.
How Can-Fite BioPharma Ltd. stacks up
CANF · against 1 other Healthcare companies of similar size
Growth
2/ 100
Near the bottom of its peers.
Ranked #2 of 2 · scores higher than 0% of peers
Bars: peers in each 10-point band of the growth score1 peers with a growth score of 0–9, including CANF · Click a bar to see the companies
Why growth scores 2?
Weighted metrics compared with all Healthcare companies.Mainly because of its revenue growth and 3-year revenue growth, which are weaker than most Healthcare peers.
- slower revenue growth over the last year: weaker than 95% of peers. Revenue growth: -39.9% vs peer median 6.1%
- slower revenue growth over three years: weaker than 94% of peers. 3-year revenue growth: -20.6% vs peer median 5.8%
- Earnings per share growth is not reported, so it is left out of the score.
Metric by metric
Position: dot = CANF, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | CANF | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Revenue growthHigher is better · 2 reported | -39.9% | 61.8% | 0% | 33% | |
| Earnings per share growthHigher is better · 0 reported | Not reported | — | — | — | 33% |
| 3-year revenue growthHigher is better · 2 reported | -20.6% | 127.7% | 0% | 33% |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by growth score
Top 5 and the companies ranked around CANF| Rank | Company | Market cap | Growth | Overall |
|---|---|---|---|---|
| 1 | 9M USD | 99 | 45 | |
| 2 | 5M USD | 2 | 27 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score